SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1.

Abstract

Listen

Translate article

BackgroundUnravelling autoimmune targets triggered by SARS‐CoV‐2 infection may provide crucial insights into the physiopathology of the disease and foster the development of potential therapeutic candidate targets and prognostic tools. We aimed at determining (a) the association between anti‐SARS‐CoV‐2 and anti‐apoA‐1 humoral response and (b) the degree of linear homology between SARS‐CoV‐2, apoA‐1 and Toll‐like receptor 2 (TLR2) epitopes.DesignBioinformatics modelling coupled with mimic peptides engineering and competition experiments were used to assess epitopes sequence homologies. Anti‐SARS‐CoV‐2 and anti‐apoA‐1 IgG as well as cytokines were assessed by immunoassays on a case‐control (n = 101), an intensive care unit (ICU; n = 126) and a general population cohort (n = 663) with available samples in the pre and post‐pandemic period.ResultsUsing bioinformatics modelling, linear sequence homologies between apoA‐1, TLR2 and Spike epitopes were identified but without experimental evidence of cross‐reactivity. Overall, anti‐apoA‐1 IgG levels were higher in COVID‐19 patients or anti‐SARS‐CoV‐2 seropositive individuals than in healthy donors or anti‐SARS‐CoV‐2 seronegative individuals (P < .0001). Significant and similar associations were noted between anti‐apoA‐1, anti‐SARS‐CoV‐2 IgG, cytokines and lipid profile. In ICU patients, anti‐SARS‐CoV‐2 and anti‐apoA‐1 seroconversion rates displayed similar 7‐day kinetics, reaching 82% for anti‐apoA‐1 seropositivity. In the general population, SARS‐CoV‐2‐exposed individuals displayed higher anti‐apoA‐1 IgG seropositivity rates than nonexposed ones (34% vs 16.8%; P = .004).ConclusionCOVID‐19 induces a marked humoral response against the major protein of high‐density lipoproteins. As a correlate of poorer prognosis in other clinical settings, such autoimmunity signatures may relate to long‐term COVID‐19 prognosis assessment and warrant further scrutiny in the current COVID‐19 pandemic.